A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas

NCT02209428 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Astrocytoma
Oligodendroglioma
Oligoastrocytoma

Interventions

DRUG: Temozolomide

Sponsor

Huashan Hospital